Study on the Safety and Effects of Pegunigalsidase Alfa for Children and Adolescents with Fabry Disease

1 1 1

What is this study about?

This clinical trial is focused on studying Fabry disease, a rare genetic condition that affects the body’s ability to break down a specific type of fat, leading to a buildup in various organs. The study is investigating a treatment called PRX-102, which is a form of enzyme replacement therapy. This treatment is given as a concentrate for solution, which is then infused into the bloodstream through a vein. The main goal of the study is to learn about the safety and effects of PRX-102 in children and adolescents aged 2 to less than 18 years who have been diagnosed with Fabry disease.

Participants in the study will receive the treatment and be monitored over a period of time to assess how their bodies respond. The study will look at various factors, including how the treatment affects the symptoms of Fabry disease, such as pain and organ function. The study will also monitor for any side effects or reactions to the treatment. Participants will be grouped into different age categories to better understand how the treatment works in different age groups.

Throughout the study, regular check-ups will be conducted to track the participants’ health and development. This includes physical exams, blood tests, and other assessments to ensure the treatment is working as intended and to identify any potential issues early on. The study aims to provide valuable information on the use of PRX-102 in young patients with Fabry disease, potentially leading to improved treatment options in the future.

1 joining the study

Upon joining the study, the patient will be assigned to one of three age groups: 2 to 7 years, 8 to 12 years, or 13 to less than 18 years.

The patient must have a confirmed diagnosis of Fabry disease, which may include specific genetic tests or symptoms such as pain or skin changes.

2 treatment administration

The patient will receive the study drug, pegunigalsidase alfa, through an intravenous infusion. This means the medication is given directly into a vein.

The medication is provided as a concentrate that is mixed into a solution for infusion.

3 monitoring and assessments

Throughout the study, the patient will undergo regular monitoring to assess safety and effectiveness. This includes checking for any side effects, such as reactions at the infusion site or changes in vital signs.

Blood and urine samples will be collected to measure specific substances related to Fabry disease, such as globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3).

4 evaluation of health and development

The patient’s growth and development will be evaluated, including height, weight, and sexual development.

Additional tests may include heart function assessments and questionnaires about pain and quality of life.

5 completion of the study

The study is expected to continue until the end of 2029. During this time, the patient will continue to receive treatment and undergo regular assessments.

If the patient reaches the age of 18 during the study, certain assessments will be adjusted to reflect adult measures.

Who Can Join the Study?

The patient must be a boy or girl aged 2 to 7 years, 8 to 12 years, or 13 to less than 18 years.
The patient must have a confirmed diagnosis of Fabry disease. For boys, this means having very low levels of a specific enzyme called alpha-galactosidase-A or a known genetic mutation causing the disease. For girls, this means having genetic test results showing Fabry mutations or having a close male relative with the disease.
The patient must have at least one of the following signs of Fabry disease: neuropathic pain (pain from nerve damage), cornea verticillata (a specific eye condition), or clustered angiokeratoma (small, dark red spots on the skin).
The patient must have a history of Fabry pain, which can be either sudden, severe burning pain starting in the hands or feet and spreading to other parts of the body, or ongoing burning and tingling sensations.
The patient’s health condition must require treatment with enzyme replacement therapy (ERT), as determined by the doctor in charge of the study.

Who Cannot Join the Study?

Patients who do not have a confirmed diagnosis of Fabry’s disease cannot participate. Fabry’s disease is a genetic condition that affects the body’s ability to break down a certain type of fat.
Patients who are not within the specified age range for the study cannot participate. The study is for children in certain age groups.
Patients who are not able to follow the study procedures or take the study medication as required cannot participate.
Patients who have other medical conditions that might interfere with the study or make it unsafe for them to participate cannot join the study.
Patients who are taking certain medications that could affect the study results cannot participate.
Patients who have had a recent major surgery or are planning to have surgery during the study period cannot participate.
Patients who are pregnant or breastfeeding cannot participate in the study.
Patients who have a history of allergic reactions to similar medications cannot participate.
Patients who are part of another clinical trial cannot participate in this study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Centre Hospitalier Universitaire De Bordeaux	Bordeaux	France

Other Sites

Site Name	City	Country
Centre Hospitalier Universitaire De Montpellier	Montpellier	France
Universidade De Santiago De Compostela	Santiago De Compostela	Spain
Uniklinikum Salzburg	Salzburg	Austria
Hzvdd Beuxtq Hd	Bergen	Norway

Trial status

Country	Status	Recruitment Start
Austria	Recruiting	30.09.2024
France	Recruiting	30.09.2024
Norway	Recruiting	30.09.2024
Spain	Recruiting	30.09.2024

Trial locations

Investigated drugs:

Pegunigalsidase Alfa

Pegunigalsidase Alfa is a medication being studied for its safety and effectiveness in treating children with Fabry disease. This medication is designed to replace a missing enzyme in patients with Fabry disease, helping to reduce the buildup of certain substances in the body that can cause damage to organs and tissues. The trial aims to understand how well this medication works in children and how it is processed by their bodies.

Investigated diseases:

Fabry's disease

Fabry Disease – Fabry disease is a rare genetic disorder caused by the buildup of a specific type of fat, called globotriaosylceramide, in the body’s cells. This accumulation occurs due to a deficiency of the enzyme alpha-galactosidase A, which is responsible for breaking down this fat. The disease primarily affects the kidneys, heart, and nervous system, leading to symptoms such as pain, kidney dysfunction, heart problems, and skin rashes. Over time, the progressive accumulation of these fats can lead to more severe complications in the affected organs. Symptoms often begin in childhood or adolescence and can vary widely in severity among individuals. The disease is inherited in an X-linked manner, meaning it predominantly affects males, although females can also experience symptoms.

Trial ID:

2022-503128-29-00

Protocol code:

CLI-06657AA1-01

NCT ID:

NCT06328608

Trial Phase:

Therapeutic use (Phase IV)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Safety and Effects of Pegunigalsidase Alfa for Children and Adolescents with Fabry Disease

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?